BRK.B FY2025: $44.5B Operating Earnings, Wildfire Risk Recedes

Berkshire Hathaway's FY2025 annual results confirm that the post-Buffett transition is proceeding more smoothly than the market's succession discount implied. Operating earnings of $44.5B were the third-highest in company history despite an insurance cycle headwind, Greg Abel deployed $9.5B on day one of his tenure via OxyChem, and PacifiCorp wildfire accruals decelerated sharply — producing three signal upgrades across our six-lens analysis. Our thesis classification of “price below value” at HIGH confidence is unchanged.

$44.5B

Operating Earnings

3rd highest ever

$369B

Cash Fortress

Post-OxyChem

84.7%

GEICO CR FY2025

10pp below danger threshold

$100M

PacifiCorp Accrual

vs $346M FY2024

FY2025: Third-Highest Operating Earnings, First Abel Acquisition

The $44.5B in operating earnings (down from $47.4B in FY2024) reflects an insurance cycle headwind and treasury reallocation — not structural deterioration. The decline is mechanical: lower catastrophe-year premiums, floating-rate treasury proceeds rolling to lower yields, and deliberate GEICO advertising investment compressing the expense ratio by 2.7 percentage points. BNSF posted +8.8% operating earnings growth and BHE delivered +6.7%, confirming the regulated asset franchises are performing.

The most consequential data point is not in the income statement. The OxyChem acquisition — closed January 2, 2026, Abel's first transaction day as CEO — directly rebuts the “savings account with conglomerate attached” bear narrative. At $9.5B, it falls below the $20B “major acquisition” threshold, but it upgrades Abel's deal-sourcing capability from theoretical to demonstrated, and the deployment math still leaves $369B in cash available.

Abel's shareholder letter (February 28, 2026) set the cultural register for the transition: operationally candid (BNSF operating ratio “too wide” vs. peers, GEICO retention pressure acknowledged), honest on impairments ($8.26B on KHC/OXY), and explicit about a five-criterion capital deployment framework. No specific new capital commitments were made — consistent with our ensemble's 85% prior probability of exactly this outcome.

Three Signals Upgraded, Zero Downgraded

FUNDING_FRAGILITY

PacifiCorp accruals $1.9B → $346M → $100M; remaining tail ≈7 weeks of BHE cash flow

STRETCHEDMANAGEABLE

NARRATIVE_REALITY_GAP

Abel's letter + OxyChem compress both bull and bear narrative distances

DIVERGINGCONVERGING

GOVERNANCE_ALIGNMENT

No new Jain sales, Abel candor, General Counsel hired, ordered CFO succession

MIXEDIMPROVING

Prediction Ensemble: 1 Resolved, 8 Updated

The Abel shareholder letter market resolved NO with a Brier score of 0.0225 — our ensemble assigned 85% probability to the “no specific capital commitment” outcome, and that is exactly what transpired. This calibration is excellent; the remaining eight active markets were updated today.

Abel shareholder letter: specific capital commitmentResolved NO ✓ Brier 0.02

PacifiCorp junk downgrade by year-end 202620% → 13%0.92 agreement

Cumulative PacifiCorp verdicts exceed $2B20% → 16%0.91 agreement

California megafire: >$5B Berkshire catastrophe losses16% → 10%0.91 agreement

Abel closes a >$10B acquisition by year-end 202623% → 35%0.87 agreement

GEICO combined ratio exceeds 95% in any 2026 quarter8% → 12%0.93 agreement

Broad-Based Risk Reduction

Seven of eight active markets moved in the direction that supports the “price below value” classification. The dominant pattern is de-risking on PacifiCorp and governance while OxyChem upgrades the capital deployment signal. The only notable upward revision — GEICO combined ratio risk rising from 8% to 12% — reflects a genuine watchlist item (expense ratio expansion), but at 12% probability with 10pp of buffer to the threshold, it does not alter the overall assessment.

What to Watch in 2026

Three monitoring triggers are now elevated for 2026 tracking:

GEICO expense ratio: FY2025 landed at 12.4% (vs 9.7% in FY2024). If advertising investment does not restore retention by Q2 2026, REVENUE_DURABILITY may face pressure. Watch the Q1 2026 10-Q for the expense ratio trend.
Abel's Form 3 / proxy filing: Greg Abel's BRK equity holdings remain the largest remaining governance data gap. The Form 3 or DEF 14A (due by mid-2026) is the next governance catalyst with 31% probability of confirming meaningful alignment.
PacifiCorp mini-trials: Weekly proceedings are ongoing. The $100M FY2025 accrual signals management's expectation, but per-case verdict averages in the first 20-30 mini-trials will be the earliest external calibration point for whether the $2.75B reserve is adequate.
HomeServices Texas antitrust: Oral arguments were heard January 14, 2026. If any judgment exceeds $1B after trebling, it would add a new stress vector to REGULATORY_EXPOSURE alongside PacifiCorp.

The Constraint That Remains

The overall posture is PROCEED_WITH_CAUTION — not a resolution. Abel's Form 3 absence (60+ days into the role), $369B still heavily underdeployed, and PacifiCorp mini-trial data not yet available keep genuine monitoring requirements in place. The improvements are real and incremental; they do not remove the need for ongoing scrutiny.

Full thesis assessment with signal ledger, market-by-market analysis, tail risk scenarios, and updated monitoring triggers

BRK.B Full Thesis Assessment Updated Analysis